Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder


    loading  Checking for direct PDF access through Ovid

Abstract

Background and ObjectivesMany patients with posttraumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse. Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ9-tetrahydrocannabinol (THC) for chronic PTSD.MethodsTen outpatients with chronic PTSD, on stable medication, received 5 mg of Δ9-THC twice a day as addon treatment.ResultsThere were mild adverse effects in three patients, none of which led to treatment discontinuation. The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms.ConclusionsOrally absorbable Δ9-THC was safe and well tolerated by patients with chronic PTSD.

    loading  Loading Related Articles